diabetes – media

Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients

Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). The US Food and Drug Administration (FDA) has cleared Kerendia (finerenone) to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction (MI) and hospitalisation for heart failure in adult patients with CKD associated with T2D. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. The drug also lowered the risk of a composite of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalisation, thereby by also meeting secondary targets. “Kerendia is the first and only nonsteroidal mineralocorticoid receptor ...
- Source: drugdu
- 1,036
- August 26, 2021
diabetes
Autoantibody order, timing predict genetically at-risk children most likely to get type 1 diabetes

by University of South Florida Children with multiple islet autoantibodies—biological markers of autoimmunity—are more likely to progress to symptomatic type 1 diabetes (T1D) than those who remain positive for a single autoantibody. Now, new findings from The Environmental Determinants of Diabetes in the Young (TEDDY) study in the U.S. and Europe show that detailed information about the order, timing and type of autoantibodies appearing after the first autoantibody can significantly improve prediction of which children are most likely to progress to type 1 diabetes more rapidly. The TEDDY analysis was published in the September 2020 issue of Diabetes Care. “A better understanding of distinct autoantibody spreading is important, because it will allow us to identify at-risk children earlier in the disease process,” said the study’s lead author Kendra Vehik, Ph.D., a professor of epidemiology at the University of South Florida Health (USF Health) Morsani College of Medicine’s Health Informatics ...
- Source: drugdu
- 521
- October 30, 2020
diabetes
Merck’s New Digital Diabetes Coaching to Educate and Manage Patients

Merck & Co. and Healthy Interactions alliance’s Map4health, a new digital and mobile service catering to diabetes patients, is designed for connecting patients with doctors to educate and help them between clinic visits.
- Source: FiercePharma
- 1,169
- August 31, 2018
Company Insight diabetes Merck mHealth
Disposable Medical Consumables – Infusion Sets

Every healthcare facility, whether it is a GP’s office, veterinary clinic, hospital ICU or dental practice, needs disposable medical consumables. As technology continues to bring healthcare to more isolated people, the demand for medical consumables also increases
- Source: Ddu
- 1,049
- August 27, 2018
diabetes infusion set Researches
New Biomarker to Prevent Severe Bouts of Low Blood Sugar in Diabetics

A new biomarker might possibly furnish new clues required to develop a diagnostic tool for hypoglycemia-associated autonomic failure (HAAF), an LSU Pennington Biomedical Research Center study found. There is no current objective diagnostic device for this life-threatening condition, if unchecked.
- Source: EurekaAlert
- 1,009
- August 16, 2018
biomarker diabetes Researches
Diabetic Eye Exams comes to Northern New York; Thanks to Telemedicine Program

Healthcare professionals in northern New York need not wait anymore for the telemedicine program designed to screen patients for diabetic retinopathy.
- Source: mHealth Intelligence
- 762
- August 13, 2018
diabetes eye test New Approvals
Europe Approves InPen; Makes Insulin Injections Easier

San Diego based Companion Medical got its InPen insulin management system certified with the European CE Mark of approval.
- Source: MedGaget
- 328
- July 26, 2018
diabetes insulin mHealth New Approvals
Johnson & Johnson Sells Calibra Diabetic Product to Cequr

Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.
- Source: MobiHealthNews
- 823
- July 19, 2018
Company Insight diabetes wearables
Medtronic Releases Results from One-Year Insulin Pump Study

On Tuesday the analysis results of a yearlong comparative study of hospital admission rates between diabetes patients using insulin pumps and those taking multiple daily injections of insulin were released by Medtronic (NYSE: MDT) and UnitedHealthcare (NYSE: UNH).
- Source: Drug Delivery Business
- 734
- July 12, 2018
diabetes Medtronic Researches
Apple Watch as Diabetes Detector

This Cardiogram work was based on Framingham Heart Study 2015, where the resting and variable heart rate significantly predicted hypertension and diabetes. This prototype helped the cardiogram research team to use the Apple Watch’s heart rate sensor for accurate diabetes predictions.
- Source: mHealthSpot
- 823
- July 3, 2018
Apple Watch Company Insight diabetes mHealth

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.